How much does retatrutide raise heart rate?

In the phase 2 obesity trial, heart rate at week 48 was 1.7, 3.1, 4.8 and 6.0 bpm above baseline at 1, 4, 8 and 12 mg, against 0.4 bpm on placebo, with the 4 mg and 8 mg figures pooled across the trial's two starting-dose arms at each of those doses. The increase was larger earlier: the publication reports that it was dose-dependent, peaked at 24 weeks and then declined at 36 and 48 weeks. The per-timepoint values behind that peak sit in a supplementary appendix that is not publicly accessible, so we do not quote a week-24 number.

Does the heart-rate increase go away?

It decreases but does not disappear within the measured period. The publication states the increase was dose-dependent, peaked at 24 weeks and was followed by a decline at 36 and 48 weeks, and the 12 mg group was still 6.0 bpm above baseline at week 48. We found no published heart-rate data beyond 48 weeks for this compound; the longer phase 3 trials have not disclosed vital signs.

Is a 6 bpm increase clinically significant?

Nobody knows for retatrutide, because no cardiovascular outcome trial for it has reported. For the approved compounds in the same class, the outcome trials reported reduced cardiovascular events despite similar heart-rate increases. Those results belong to those molecules and cannot be carried across to retatrutide in either direction.

Does retatrutide raise heart rate more than tirzepatide?

Directionally, the available estimates suggest yes, but the difference is not established. Pooled estimates against placebo put retatrutide at 3.46 bpm (95 percent CI 1.74 to 5.18) and tirzepatide at 2.05 bpm (0.96 to 3.13), intervals that overlap substantially. No head-to-head trial has reported, the retatrutide estimate comes from a single phase 2 trial, and every comparison available today is therefore indirect. A phase 3 head-to-head against tirzepatide in 800 adults with obesity is enrolled, with primary completion registered for November 2026.

What happened to blood pressure in the same trial?

It fell while heart rate rose. The publication reports improvements in systolic and diastolic blood pressure, glycated haemoglobin, fasting glucose, insulin and lipids, with the exception of HDL cholesterol, as exploratory endpoints at weeks 24 and 48. The per-measure figures are in a supplementary appendix we cannot access, so we quote the two consequences printed in the main text instead: improvements in blood pressure led to discontinuation of at least one antihypertensive medication in 41 percent of the combined 8 mg group and 30 percent of the 12 mg group, and 72 percent of retatrutide participants who had prediabetes at baseline had reverted to normoglycemia by week 48 against 22 percent on placebo. Reporting the heart-rate rise without these changes would misrepresent the trial.

Is there any data on retatrutide and heart-rate variability?

We searched specifically and found none. We could locate no published trial measuring HRV under retatrutide, and none under tirzepatide either. The only proper human HRV trial we located in this drug class used liraglutide.

What did that liraglutide HRV trial find?

In a crossover trial with 27 evaluable participants, liraglutide reduced SDNN by 33.9 ms on 24-hour Holter monitoring, reduced RMSSD, and raised mean heart rate by 8.1 bpm compared with placebo. It is a small trial in a different compound, and other analyses point the other way: a post-hoc analysis of 4,769 people in the GRADE cohort found no difference in incident cardiac autonomic neuropathy and actually higher SDNN at year two with liraglutide.

Can a wearable HRV drop be attributed to the compound?

It cannot be determined from the reading itself. HRV responds to sleep, alcohol, illness, heat, dehydration, training load, stress and energy deficit, and consumer readings vary substantially night to night in the same person. A single low reading carries almost no information. There is also no HRV trial data for this compound that we could locate to compare against.

Is fatigue a documented side effect of retatrutide?

Yes. The phase 2 publication lists fatigue among the adverse events occurring in at least 5 percent of participants: 6 of 62 (10 percent) at 12 mg and 22 of 337 (7 percent) across all retatrutide arms, against 3 of 70 (4 percent) on placebo. The intermediate arms held 33 to 35 participants each, so the ordering between them is not interpretable. The separate term asthenia does not appear as its own row in the publication's adverse-event table, so this rate is narrower than the pooled fatigue term used on the tirzepatide label.

How do the online fatigue percentages compare with the trial?

More closely than usual, which is the interesting part. An academic analysis of self-reports on a public discussion platform, posted as a preprint in June 2026 and not peer reviewed, found that 15.2 percent of 7,823 retatrutide users with at least one mapped symptom mentioned fatigue. The trial recorded 10 percent at 12 mg against 4 percent on placebo. Self-reported tallies normally run several times above trial rates, and here they do not. The two still cannot be equated: the online denominator is people who chose to post, incidence and causality cannot be estimated from it, and product identity, purity and dose are unknown.

How many people online actually report a heart-rate problem?

A minority of those reporting anything. In the same analysis of 7,823 users with a mapped symptom term, 4.8 percent mentioned an increased heart rate, 3.8 percent tachycardia, 1.9 percent palpitations and 0.6 percent decreased heart-rate variability, with the cardiac disorders class overall at 5.9 percent. A peer-reviewed companion analysis of 29,172 semaglutide and tirzepatide users reporting side effects, published in Nature Health in April 2026, found 1.8 percent mentioning tachycardia and 0.7 percent palpitations. These are hypothesis-generating figures from a self-selected group, not incidence rates.

Are the videos warning about retatrutide and heart rate reliable?

We cannot tell you, and we will not pretend otherwise. We confirmed that videos exist under titles framing retatrutide's heart-rate effect as a danger, and we confirmed the identities of two of the people publishing them from public licensing registries: one is listed as a chiropractor in Colorado and one as a licensed acupuncturist in Utah, and both sell paid peptide or GLP-1 programmes. What we could not retrieve is the content of any of those videos, because automated access returns no description and no transcript. So we make no statement about what they claim. The remaining videos we found come from anonymous channels with no verifiable credential at all.

Does eating too little make the cardiac effects worse?

It is plausible and untested. A large energy deficit is independently documented to raise resting heart rate and lower heart-rate variability, in studies of lean and athletic populations without any drug. We found no study testing whether energy intake changes cardiac measures or fatigue in anyone using retatrutide, so this remains an extrapolation from adjacent physiology rather than a finding about this compound.

Is there a recommended rate of weight loss or protein intake for this situation?

Not one we could source. We looked for a numeric guideline on a safe rate of pharmacologically induced weight loss and found none in the literature; the reviews that address lean-mass preservation propose frameworks rather than thresholds. We are not going to publish a number we cannot source, and figures circulating in vendor and forum content should be treated as uncited until someone points to a study for them.

What about palpitations or atrial fibrillation?

The retatrutide trial itself reports on this. Cardiac arrhythmia was an adverse event of special interest in the phase 2 study, covering supraventricular arrhythmias and cardiac conduction disorders: 19 of 337 (6 percent) across the retatrutide arms against 2 of 70 (3 percent) on placebo, and 7 of 62 (11 percent) at 12 mg. The counts are small and do not rise cleanly with dose, and the publication states the reported arrhythmias were mild to moderate apart from one severe prolonged-QT event in a participant who was also taking ondansetron. For the approved comparators, the Mounjaro label reports episodes of sinus tachycardia associated with a concomitant increase from baseline in heart rate of at least 15 bpm in 4.3 percent on placebo against 4.6, 5.9 and 10 percent at 5, 10 and 15 mg tirzepatide, in its type 2 diabetes pool. At population level, a retrospective cohort across more than 220 healthcare organisations found GLP-1 receptor agonist use associated with a lower rate of new-onset atrial fibrillation. Isolated tirzepatide case reports also exist; single case reports establish that something can happen, not how often.

Who was excluded from the retatrutide trial?

According to the trial's registry record and publication, people with type 1 or type 2 diabetes, people who had had a heart attack, a stroke or a hospitalisation for congestive heart failure in the previous three months, people with uncontrolled high blood pressure, and people who had had obesity surgery or were taking medication affecting body weight. The full eligibility list sits in a supplementary appendix that is not publicly accessible, so we report only the criteria a reader can check. Every heart-rate figure quoted here comes from a population screened for recent cardiac events.

Is retatrutide approved, and how do you supply it?

It is not approved anywhere. We supply it as a research compound for laboratory use only, not for human consumption, with our supplier's batch-specific third-party laboratory report published on our CoA page. We give no dosing, protocol or usage recommendations.

Retatrutide, Heart Rate and HRV: What the Trials Measured and What Nobody Has Measured

Important notice: This article reports published clinical research for scientific information only. Retatrutide is an investigational compound with no marketing authorisation anywhere, supplied by us as a research chemical and not for human consumption. We sell retatrutide and tirzepatide as research compounds, which gives us an obvious interest in how this reads. Nothing here is a dosing recommendation, a protocol, a nutrition plan or medical advice, and no part of it should be read as guidance on what anyone should take, eat or do. Trial doses are reported as study facts.

TL;DR: the numbers that exist, and the ones that do not

The measured rise: in the phase 2 obesity trial, heart rate at week 48 was 6.0 bpm above baseline at the 12 mg dose, against 0.4 bpm on placebo. The trial reports the increase as dose-dependent, peaking at 24 weeks and declining at 36 and 48 weeks. The other half of that trial: in the same participants, blood pressure moved down while heart rate moved up. The publication reports improvements in systolic and diastolic blood pressure, glucose, insulin and lipids as exploratory endpoints, and 41 percent of the combined 8 mg group stopped at least one antihypertensive medication during the 48 weeks. Against the class: pooled estimates put retatrutide at 3.46 bpm above placebo, tirzepatide at 2.05 and semaglutide at 3.35, with heavily overlapping confidence intervals and no head-to-head trial reported yet. A phase 3 head-to-head against tirzepatide is enrolled, with primary completion registered for November 2026. On heart-rate variability: we searched specifically, and found no published trial measuring HRV under retatrutide or tirzepatide. One exists for liraglutide and reports reduced variability; a much larger cohort analysis points the other way. On feeling drained: the phase 2 trial does report a fatigue rate, and it is rarely quoted: 10 percent at 12 mg against 4 percent on placebo, close to the pattern on the tirzepatide label. An academic analysis of public forum posts puts self-reported fatigue at 15.2 percent, which is the same rough range rather than a wild inflation. The unknown that matters most: no cardiovascular outcome trial for retatrutide has reported, so whether the heart-rate rise carries any clinical consequence is unknown in both directions.

Retatrutidemetabolic

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

Why this question is harder than it looks

A search for retatrutide side effects returns the gastrointestinal list everywhere: nausea, diarrhea, vomiting. What people actually ask in forums is narrower and more specific. My resting heart rate is up six beats. My HRV has been in the basement for three weeks. I feel wrung out. Is that the compound, is it the deficit, or is it my sleep?

That question is answerable, but not in the way most articles pretend. The heart-rate part has real trial data behind it. On the variability part we could locate no trial at all. And the fatigue part has exactly one trial number, buried in an adverse-event table that almost nobody quotes, sitting next to a set of online self-report tallies that count something different and, on this particular symptom, turn out to land surprisingly close to it.

This article separates those three cases, because conflating them is how the bad advice gets made.

What the trial actually recorded

The phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine 2023) randomised 338 adults across seven arms for 48 weeks. Change in heart rate and blood pressure from baseline to weeks 24 and 36, assessed by 24-hour ambulatory monitoring, was a prespecified exploratory endpoint. Heart rate was also recorded through week 48, and that later series is the one a reader can check.

Start with the week-48 readings. The trial ran seven arms and tabulates each of them separately, splitting 4 mg and 8 mg by starting dose; the figures below are those arms pooled by target dose, as the 2026 meta-analysis extracted them.

Dose group	Baseline heart rate	Change at week 48
Placebo	74.0 bpm	+0.4 bpm
Retatrutide 1 mg	71.1 bpm	+1.7 bpm
Retatrutide 4 mg	69.9 bpm	+3.1 bpm
Retatrutide 8 mg	70.6 bpm	+4.8 bpm
Retatrutide 12 mg	69.3 bpm	+6.0 bpm

Placebo

Baseline heart rate: 74.0 bpm
Change at week 48: +0.4 bpm

Retatrutide 1 mg

Baseline heart rate: 71.1 bpm
Change at week 48: +1.7 bpm

Retatrutide 4 mg

Baseline heart rate: 69.9 bpm
Change at week 48: +3.1 bpm

Retatrutide 8 mg

Baseline heart rate: 70.6 bpm
Change at week 48: +4.8 bpm

Retatrutide 12 mg

Baseline heart rate: 69.3 bpm
Change at week 48: +6.0 bpm

That is a clean dose gradient: every step up the dose ladder adds roughly one to two beats, and the top dose lands at 6.0 bpm above baseline against 0.4 bpm on placebo.

The trial also ran 24-hour ambulatory monitoring at weeks 24 and 36, and that is where the shape of the effect comes from. The publication describes it twice and in both places without a number in the main text: the heart rate "increased in a dose-dependent manner with retatrutide up to 24 weeks and then declined thereafter", and in the discussion, it "increased with retatrutide treatment in a dose-dependent manner, peaking at 24 weeks, followed by a decline at 36 and 48 weeks; the increases were similar to those reported for GLP-1 receptor agonists".

Why you will not find a week-24 ambulatory number on this page

The per-timepoint ambulatory tables sit in the trial's supplementary appendix, which is behind the journal's paywall. We could not open it, and we could not find a secondary source quoting those values that we could check. So this article reports the week-48 figures, which a reader can verify in an open-access meta-analysis, and reports the peak-at-24-weeks pattern in the words the trial itself used. Anything we cannot point you to, we leave out.

Three things that make these numbers interpretable

The baseline matters. The 12 mg group started at 69.3 bpm, so a 6.0 bpm rise is roughly a 9 percent relative increase from where those participants began. Note also that the placebo group started higher, at 74.0 bpm, than any retatrutide arm, which is the kind of baseline imbalance a 338-person trial across seven arms produces and a reason to read the change columns rather than compare end values across arms. The population was screened. People with diabetes were excluded, as were people with a heart attack, a stroke or a hospitalisation for congestive heart failure in the three months before entry, and people with uncontrolled high blood pressure. These figures describe a population selected to be free of recent cardiac events. The shape and the size come from different measurements. The peak-then-decline pattern is the trial's description of its ambulatory series at weeks 24 and 36. The numbers in the table above are the week-48 readings, which is after the decline the trial describes. Both statements are from the same trial, but they are not two views of one number, and the week-24 peak is larger than 6.0 bpm by an amount the publication does not print in its main text.

The half of the trial that rarely gets quoted

An article that reports the heart-rate rise and stops there is not being careful, it is being selective. The same participants, measured at the same visits, moved the other way on almost everything else.

Here the per-measure numbers are in the same inaccessible appendix, so we report the publication's own summary rather than figures we cannot show you. Retatrutide treatment "was associated with improvements in cardiometabolic measures (exploratory end points) including systolic and diastolic blood pressure and levels of glycated hemoglobin, fasting glucose, insulin, and lipids (with the exception of high-density lipoprotein [HDL] cholesterol) at weeks 24 and 48".

Two consequences of that are printed in the main text, and they are more informative than a decimal place anyway:

Blood pressure fell far enough to change medication. Improvements in blood pressure over the 48 weeks led to discontinuation of at least one antihypertensive medication in 41 percent of participants in the combined 8 mg group and 30 percent in the 12 mg group. That is a clinical decision made by investigators, not a modelled delta.
Glucose moved with it. At week 48, 72 percent of retatrutide participants who had prediabetes at baseline had reverted to normoglycemia, against 22 percent on placebo.

So the honest one-sentence version of this trial's cardiovascular picture is that heart rate went up while blood pressure, lipids and glucose went down. Whether that trade is favourable, neutral or unfavourable over years is exactly the question a cardiovascular outcome trial exists to answer, and retatrutide does not have one that has reported.

Is retatrutide worse for heart rate than tirzepatide?

This is the specific comparison the community argues about, so it deserves the actual numbers rather than a vibe.

A 2026 systematic review pooled the incretin trials in people with overweight or obesity without diabetes. The pairwise estimates against placebo:

Compound	Mean heart-rate difference vs placebo
Tirzepatide	+2.05 bpm (95 percent CI 0.96 to 3.13)
Liraglutide	+2.37 bpm (1.86 to 2.89)
Semaglutide	+3.35 bpm (1.69 to 5.01)
Retatrutide	+3.46 bpm (1.74 to 5.18)
Oral semaglutide	+4.50 bpm (3.11 to 5.89)
Orforglipron	+7.30 bpm (5.48 to 9.12)

Tirzepatide

Mean heart-rate difference vs placebo: +2.05 bpm (95 percent CI 0.96 to 3.13)

Liraglutide

Mean heart-rate difference vs placebo: +2.37 bpm (1.86 to 2.89)

Semaglutide

Mean heart-rate difference vs placebo: +3.35 bpm (1.69 to 5.01)

Retatrutide

Mean heart-rate difference vs placebo: +3.46 bpm (1.74 to 5.18)

Oral semaglutide

Mean heart-rate difference vs placebo: +4.50 bpm (3.11 to 5.89)

Orforglipron

Mean heart-rate difference vs placebo: +7.30 bpm (5.48 to 9.12)

Why that table cannot settle the argument

The confidence intervals matter more than the point estimates here. Retatrutide's interval (1.74 to 5.18) overlaps tirzepatide's (0.96 to 3.13) across most of its range. The retatrutide estimate rests on a single phase 2 trial, while the tirzepatide estimate draws on much larger phase 3 trials. And no head-to-head trial of retatrutide against tirzepatide has reported on heart rate or on anything else, so every comparison here is indirect: different trials, different populations, different measurement methods, different timepoints. One such trial is running: a phase 3 comparison against tirzepatide in 800 adults with obesity, registered with primary completion in November 2026. Until it reads out, the directional claim that retatrutide raises heart rate somewhat more than tirzepatide is supported, and a precise difference between them is not.

The individual trial numbers tell the same story with the same caveat. In SURMOUNT-1, the 72-week phase 3 tirzepatide trial in 2,539 adults, mean heart-rate change was +0.6, +2.3 and +2.6 bpm at 5, 10 and 15 mg against +0.1 on placebo. In STEP 8, semaglutide 2.4 mg produced +5.4 bpm against +1.2 on placebo. Retatrutide's +6.0 bpm at 12 mg in the table above is the largest of the three, and it also comes from the shortest trial: 48 weeks against 68 in STEP 8 and 72 in SURMOUNT-1. Size is not the difference. STEP 8 randomised 338 people, exactly as many as the retatrutide phase 2; what separates them is duration, phase and the number of trials behind each estimate.

What the approved labels say, which is not nothing

Retatrutide has no label because it is not approved. Its approved cousins do, and they are not identical. Wegovy (semaglutide) is the only one of the four major labels with a dedicated Warnings and Precautions section for heart-rate increase, section 5.9. Zepbound, Mounjaro and Ozempic mention heart rate only under Adverse Reactions. Tirzepatide carries two labels, and they describe different populations. Mounjaro, in its placebo-controlled type 2 diabetes pool, reports a mean increase of 2 to 4 bpm against 1 bpm on placebo, and reports episodes of sinus tachycardia associated with a concomitant increase from baseline in heart rate of at least 15 bpm in 4.3 percent on placebo against 4.6, 5.9 and 10 percent at 5, 10 and 15 mg. Zepbound, in the obesity trials, reports a mean increase of 1 to 3 bpm, including the +2.6 bpm at 15 mg quoted above from SURMOUNT-1. Those are two different pools and the figures cannot be subtracted from one another, but read side by side they make one point that a single mean cannot: inside the diabetes pool, an average in the low single digits coexisted with roughly one in ten participants at the top dose recording a sinus-tachycardia episode with a 15 bpm rise. A mean hides the tail.

Does the rise translate into harm?

For the approved compounds, the outcome trials are the closest thing to an answer, and they run the other way.

SELECT randomised 17,604 people with cardiovascular disease and no diabetes to semaglutide 2.4 mg or placebo and reported a major adverse cardiovascular event hazard ratio of 0.80.
LEADER reported a hazard ratio of 0.87 for liraglutide, with cardiovascular death at 0.78.
SUSTAIN-6 reported 0.74 for the composite, although cardiovascular death itself was not reduced.
SURPASS-CVOT compared tirzepatide against dulaglutide, an active comparator with its own proven benefit, and found tirzepatide non-inferior but not superior.
A 2026 network meta-analysis found subcutaneous semaglutide the only drug associated with reduced all-cause mortality (risk ratio 0.81) and myocardial infarction (0.72), with semaglutide (0.43) and tirzepatide (0.49) reducing heart-failure risk.
A retrospective cohort across more than 220 healthcare organisations found GLP-1 receptor agonist use associated with a lower rate of new-onset atrial fibrillation (hazard ratio 0.924).

What none of that establishes for retatrutide

Every one of those results belongs to a different molecule. No cardiovascular outcome trial for retatrutide has reported. The dedicated one, TRIUMPH-Outcomes, is enrolled at 10,000 participants and registered with primary completion in February 2029. TRIUMPH-3, the phase 3 trial conducted in a population with established cardiovascular disease, reported weight and risk-factor results in July 2026 with major adverse cardiovascular events rarer than the trial anticipated, which left all four reported hazard ratios, in-study and on-treatment for both the five-component and the three-component composite, with confidence intervals crossing 1.0. That is not evidence of harm, and not evidence of safety. The honest position on retatrutide and cardiac outcomes in 2026 is that nobody knows, and anyone claiming otherwise in either direction is filling the gap with something other than data.

Heart-rate variability: the part with no data at all

This is the measurement most people are actually watching, because their wearable shows it every morning. So we searched for it specifically, across GLP-1, GIP and glucagon agonists, autonomic function, sympathetic activity, baroreflex sensitivity and cardiac autonomic neuropathy.

We found no published trial measuring heart-rate variability under retatrutide. None under tirzepatide either. That is a statement about what we could locate, not a proof that no such data exists anywhere, but the search was deliberate and it came back empty.

What does exist, in older and adjacent compounds, is genuinely mixed:

A liraglutide crossover trial in 27 people is the only proper human HRV trial we found in this class. Against placebo it reported SDNN falling by 33.9 ms over 24-hour Holter monitoring, RMSSD falling, and mean heart rate rising 8.1 bpm. That is the finding that supports the worry.
A post-hoc analysis of the randomised GRADE cohort, 4,769 participants with ECG-derived measures, found no difference in incident cardiac autonomic neuropathy between treatment groups, and SDNN actually higher at year two with liraglutide. That is the finding that contradicts it.
A meta-analysis of chronic GLP-1 treatment in diabetes found heart rate significantly increased while the LF/HF ratio did not change.
A 30-week semaglutide randomised trial, in adults on second-generation antipsychotics of whom 84 percent already had autonomic neuropathy at baseline, found no change in that status.
A mechanistic randomised study in 57 people found the heart-rate rise on exenatide was not explained by sympathetic nervous system activity, and an acute study found GLP-1 raised muscle sympathetic nerve activity without changing cardiac sympathetic or parasympathetic indices.

The closest thing to what wearable users see

One study did measure exactly this. In 66 GLP-1 users tracked for 12 weeks with a consumer wearable, resting heart rate rose 3.2 bpm and heart-rate variability fell 6.2 ms, while weight fell 10.0 percent. The mediation runs in the direction people usually get backwards: the analysis found the rise in resting heart rate was statistically mediated by the fall in heart-rate variability, that is by the autonomic measure, not by the weight change. Two caveats that matter as much as the result: six of the seven authors are affiliated with the device manufacturer, and statistical mediation is not experimental proof of a causal path. It is nonetheless the only dataset we located that measures the thing people are worried about in the population they belong to.

Why a wearable can show all of this without the compound being the cause

A falling HRV and a rising resting heart rate are among the least specific signals in physiology. They respond to sleep loss, alcohol, illness, heat, dehydration, training load, psychological stress and, importantly here, energy deficit.

The under-eating literature is old and consistent. The Minnesota semi-starvation experiment in 36 conscientious objectors documented the syndrome that goes with sustained large deficits. Modern low-energy-availability work, including a randomised crossover in 19 active adults comparing 15 against 45 kcal per kilogram of fat-free mass per day, documents measurable metabolic and subjective changes within days.

Read that literature with its label on

Those studies were done in lean, mostly athletic people, without any drug, under enforced protocols. They describe the physiology of a large energy deficit in general. They are not studies of anyone using an incretin compound, and using them to explain what a specific person experiences is an extrapolation, not a finding. We include them because the mechanism is plausible and because energy deficit is a confounder that any interpretation of these signals has to account for, not because anyone has demonstrated it in this setting.

There is also a measurement problem. Consumer HRV readings vary substantially night to night in the same person under identical conditions, which means a single low morning reading carries almost no information, and a two-week trend carries some. Anyone comparing their own numbers across weeks of rapid weight loss is looking at a signal with several inputs and no way to separate them at home.

The fatigue question, and the trial number nobody quotes

The phase 2 publication does report a fatigue rate. It sits in the Table 3 block listing adverse events that occurred in at least 5 percent of all participants, and it is quoted so rarely that the idea took hold that no such number exists.

Group	Participants reporting fatigue
Placebo	3 of 70 (4 percent)
Retatrutide 1 mg	3 of 69 (4 percent)
4 mg, initial dose 2 mg	4 of 33 (12 percent)
4 mg, initial dose 4 mg	2 of 33 (6 percent)
8 mg, initial dose 2 mg	1 of 35 (3 percent)
8 mg, initial dose 4 mg	3 of 35 (9 percent)
12 mg	6 of 62 (10 percent)
All retatrutide arms	22 of 337 (7 percent)

Placebo

Participants reporting fatigue: 3 of 70 (4 percent)

Retatrutide 1 mg

Participants reporting fatigue: 3 of 69 (4 percent)

4 mg, initial dose 2 mg

Participants reporting fatigue: 4 of 33 (12 percent)

4 mg, initial dose 4 mg

Participants reporting fatigue: 2 of 33 (6 percent)

8 mg, initial dose 2 mg

Participants reporting fatigue: 1 of 35 (3 percent)

8 mg, initial dose 4 mg

Participants reporting fatigue: 3 of 35 (9 percent)

12 mg

Participants reporting fatigue: 6 of 62 (10 percent)

All retatrutide arms

Participants reporting fatigue: 22 of 337 (7 percent)

Two things about that column. The middle arms held 33 to 35 people each, so a single participant moves them by three percentage points and the ordering between them carries no information. And the term counted is fatigue alone: asthenia does not appear as a separate row in the publication's adverse-event table, so the retatrutide figure is narrower than the label figures below, which pool several related terms.

The comparator that makes those numbers readable comes from the approved compounds. The Zepbound label reports fatigue, defined there to include asthenia, lethargy and malaise, in 3 percent on placebo against 5, 6 and 7 percent at 5, 10 and 15 mg tirzepatide. Retatrutide's 10 percent at 12 mg against 4 percent on placebo lands almost on top of that pattern: a drug-attributable share of a few percentage points on a substantial background rate, which is the expected shape for a symptom this common.

Larger percentages circulate online. They are examined in the section on community reports below, and the short version is that on fatigue specifically they are not as far from the trial as you would expect.

A 2026 network meta-analysis of 19 weight-management drugs did find fatigue risk increased across the class, naming naltrexone-bupropion, orforglipron and CagriSema as showing the largest increases. It does not report a null for the compounds discussed here; it simply does not single them out.

The two community claims, examined

Claim one: that under-eating makes it much worse

This is the most repeated claim in the enthusiast community and in vendor content. What supports it: the general physiology of a large energy deficit, which does raise resting heart rate and lower HRV, and the fact that appetite suppression makes a large deficit easy to fall into without noticing. What does not support it: we found no randomised or observational study testing whether energy intake changes fatigue severity or cardiac measures in anyone using retatrutide. The claim is a plausible extrapolation from adjacent physiology, and it has never been tested in this setting. We are not going to convert it into an intake recommendation, because there is no evidence base to set one from, and because we searched for a numeric guideline on a safe rate of pharmacologically induced weight loss and found none in the literature.

Claim two: that a stronger compound for the loss phase and a milder one for maintenance is the sensible pattern

This circulates widely, including in commercial content from companies selling both. Two facts are worth knowing about it. First, we found no clinical trial testing any switch between these compounds for any purpose, and the only published switching work we located is a modelling exercise pointed in the opposite direction. Second, where this pattern is argued for commercially, the stated reasons are usually gastrointestinal tolerability, cost and potency being unnecessary at goal weight, not cardiac burden; the cardiac rationale does not appear in the commercial arguments we could find. Retatrutide additionally has no published maintenance or withdrawal data that we could locate, so there is not even indirect evidence about what happens after stopping it.

What is actually documented about stopping

Only for the approved compounds. The semaglutide programme included a withdrawal design in which heart rate fell by 5.3 bpm in the group taken off the drug against 2.0 bpm in the group continuing, which at least establishes that the heart-rate effect is treatment-dependent and reverses. We found no equivalent measurement for retatrutide.

What the creators and the communities say

Search this topic on video platforms and you land in a different corpus from the one above: titles that frame retatrutide's effect on the heart as a danger. Most of those channels are anonymous. Two of the publishers can be identified with confidence, because their names appear in the public registries that license them, and both of them sell something adjacent to the subject.

Dean Jones, who publishes as "Dr. Jones, DC". The US National Provider Identifier registry lists him as a chiropractor in Colorado, not a physician. His clinic sells a paid GLP-1 and peptide support programme, which is a direct commercial interest in this exact question. His video is titled "Doctor Explains The Side Effects of Retatrutide (Heart Issues, Cancer & More)".
Regan Archibald, whose registry entry lists him as a licensed acupuncturist in Utah. He sells peptide programmes and courses. His video is titled "Does Retatrutide Increase Heart Rate".

What we checked, and the one thing we could not

We confirmed two things: that these videos exist under those titles, and who these two people are according to the registries that license them. We could not confirm the third and most important one, which is what either video actually says. Automated retrieval returns boilerplate with no description and no transcript, so we have not reviewed the content, and nothing on this page should be read as a description of what either person claims. We also do not repeat the credentials they are given elsewhere, because a registry entry is checkable and a self-description is not. The remaining videos we found on this topic come from anonymous channels with no verifiable credential behind them, and we do not name those at all.

One named clinician quote on this subject is verifiable, and it is worth printing. Medscape Medical News, reporting on retatrutide obtained outside approved channels, quoted Courtney Younglove, MD, of Heartland Weight Loss, saying: "What's happening now is a huge, unregulated human experiment." Two qualifications belong with it. She runs a commercial weight-loss clinic, which is a vantage point with its own interests. And the quote is about unapproved use in general, not about heart rate, so it is not a comment on any figure on this page.

The part of the community evidence that has numbers

The useful material here is not anyone's video. It is two academic analyses that read a public discussion platform at scale, classified what users said with a language model and mapped it onto standard adverse-event terminology. That produces percentages instead of anecdotes, and it means we are citing researchers rather than reading forums ourselves.

The retatrutide-specific analysis, posted as a preprint in June 2026 and not peer reviewed, worked from 7,823 users with at least one mapped symptom term:

Term reported	Share of those 7,823 users
Increased appetite	17.1 percent
Fatigue	15.2 percent
Heart rate increased	4.8 percent
Tachycardia	3.8 percent
Palpitations	1.9 percent
Decreased heart-rate variability	0.6 percent
Cardiac disorders, the whole class	5.9 percent

Increased appetite

Share of those 7,823 users: 17.1 percent

Fatigue

Share of those 7,823 users: 15.2 percent

Heart rate increased

Share of those 7,823 users: 4.8 percent

Tachycardia

Share of those 7,823 users: 3.8 percent

Palpitations

Share of those 7,823 users: 1.9 percent

Decreased heart-rate variability

Share of those 7,823 users: 0.6 percent

Cardiac disorders, the whole class

Share of those 7,823 users: 5.9 percent

Its companion analysis of semaglutide and tirzepatide is a step further along: it was published, peer reviewed, in Nature Health in April 2026. Among 29,172 users reporting at least one side effect, fatigue ran at 16.7 percent, asthenia 2.5 percent, tachycardia 1.8 percent and palpitations 0.7 percent.

The comparison worth making

Put the fatigue figures next to each other. The trial recorded 10 percent at the 12 mg dose against 4 percent on placebo. The community analysis recorded 15.2 percent. Those are the same rough range, and that is not the usual result. Self-reported symptom tallies normally run several times above trial rates, and on this symptom they do not. Whatever else the posts are, on fatigue they are not wildly inflated relative to what the trial measured.

Heart rate reads differently. Among users with a mapped symptom, 4.8 percent mentioned an increased heart rate at all, 3.8 percent tachycardia and 1.9 percent palpitations, with the entire cardiac class at 5.9 percent. Decreased heart-rate variability, the measurement the wearable-owning part of this audience watches every morning, was mentioned by 0.6 percent. The topic that dominates the video titles is a minority report in what people actually write.

One row in that table needs a warning label rather than a headline. Increased appetite sits at the top partly by construction: the researchers deliberately excluded appetite-suppression terms before computing the denominator, so a table built that way will place appetite increase near the top regardless of the underlying reality. It is not the counterintuitive inversion it looks like, and we are not going to present it as one.

How much weight these percentages carry, in the authors' own words

The authors state the constraints themselves, and they are severe. The findings are hypothesis-generating. The people posting are not representative of the people using the compound, and those experiencing adverse events are more likely to post in the first place. Incidence and causality cannot be estimated. Product identity, purity, dose, duration and concurrent drugs cannot be determined, so any given effect may reflect product quality, the use of several unapproved compounds at once, or misattribution rather than the compound named. The retatrutide analysis is a preprint and has not been peer reviewed; the semaglutide and tirzepatide analysis has been. A co-author on both papers reports an investigator-initiated grant from Novo Nordisk and consulting fees from another pharmaceutical company. Read these percentages as a map of what a self-selected group talks about, not as a rate in any population.

What would actually settle these questions

Three studies would resolve most of this, and none of them has reported. A cardiovascular outcome trial powered on events rather than on weight would establish whether the heart-rate rise matters clinically; TRIUMPH-3 was not designed to answer that and did not, and TRIUMPH-Outcomes, which was, is registered with primary completion in February 2029. An HRV substudy inside any incretin trial would replace the current void with data, and these programmes already carry out ambulatory cardiovascular monitoring. And a head-to-head trial against tirzepatide would replace every indirect comparison in this article, including the one in our own table; that trial is enrolled at 800 participants with primary completion registered for November 2026.

One symmetry is worth stating, because this article spends more space on the arguments for switching away than on the alternative. Continuing retatrutide indefinitely is no better evidenced than switching off it. Neither has been studied, and the absence cuts both ways.

Until then, the state of knowledge is: a well-measured heart-rate increase that is dose-dependent and partially reverses, alongside reductions in blood pressure and lipid measures in the same participants, one 48-week trial fatigue rate, no variability data we could locate, no outcome data and no head-to-head readout.

How we report this

Our position, stated with the commercial interest disclosed at the top of this page in mind, is that the useful version of a side-effect article is the one that separates measured from unmeasured and refuses to fill the gaps. Everything above is sourced, and where we could find nothing we have said so rather than substituting a mechanism story. Our supplier batch reports for both compounds, from a third-party laboratory, are published per batch on our CoA page, and the broader safety picture is covered in our retatrutide side-effect profile and the TRIUMPH-2 and TRIUMPH-3 readout.

The compounds discussed here

Metabolic Researchmetabolic

GIP/GLP-1/Glucagon agonists and metabolic pathways

The triple agonist in this article

Retatrutidemetabolic

The comparators

Tirzepatidemetabolic

A first-in-class dual GIP and GLP-1 receptor agonist, and one of the most extensively studied compounds in modern metabolic and weight-regulation research. Supplied as a lyophilised research peptide with a per-batch certificate of analysis, for laboratory and in-vitro use only.

Cagrilintidemetabolic

Long-acting amylin analog studied for once-weekly satiety and appetite control. Phase 3 REDEFINE trials complete, NDA filed with FDA December 2025. A mechanism distinct from GLP-1 agonists.

AOD-9604metabolic

Modified hGH fragment (177-191) studied for fat metabolism and lipolysis research. Interacts with beta-3 adrenergic receptors without growth-promoting effects.

FAQ

Sources

Jastreboff AM, Kaplan LM, Frias JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial." New England Journal of Medicine 2023;389(6):514-526. PMID 37366315. Main text only. Table 3 is the source of the fatigue, cardiac-arrhythmia and hyperaesthesia counts, and the results and discussion sections are the source of the peak-at-24-weeks description, the cardiometabolic summary, the antihypertensive-discontinuation and normoglycemia figures and the severity of the reported arrhythmias. The trial's supplementary appendix, which holds the per-timepoint ambulatory heart-rate and blood-pressure tables and the full eligibility list, is behind the journal's paywall; we could not open it and we quote nothing from it. https://pubmed.ncbi.nlm.nih.gov/37366315/
Zhang Y, Zhang C, Gong X, et al. "Effect of GLP-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: systematic review and pairwise and network meta-analysis." European Journal of Medical Research 2026;31(1):318. PMID 41582189, DOI 10.1186/s40001-026-03933-9. Open access. Table 1 is the source of the week-48 heart-rate figures in this article, pooled by target dose from the trial's seven arms; the pairwise and network estimates are from its results section. Twelve articles entered the pairwise analysis and eleven the network analysis. https://pubmed.ncbi.nlm.nih.gov/41582189/
Nong K, Shi Q, Xie H, et al. "Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis." BMJ 2026. PMID 42419792. https://pubmed.ncbi.nlm.nih.gov/42419792/
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT). New England Journal of Medicine 2023;389:2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
Marso SP, Daniels GH, Brown-Frandsen K, et al. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes" (LEADER). New England Journal of Medicine 2016;375:311-322. https://pubmed.ncbi.nlm.nih.gov/27295427/
Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine 2022;387:205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
US Food and Drug Administration prescribing information: ZEPBOUND (tirzepatide), MOUNJARO (tirzepatide), WEGOVY (semaglutide) and OZEMPIC (semaglutide), current labelling as published on DailyMed, 2026. The sinus-tachycardia rates come from the MOUNJARO type 2 diabetes pool, the +2.6 bpm and the fatigue rates from the ZEPBOUND obesity trials, and the withdrawal heart-rate figures from the WEGOVY label.
Kumarathurai P, Anholm C, Larsen BS, et al. "Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study." Diabetes Care 2017;40(1):117-124. PMID 27797930. https://pubmed.ncbi.nlm.nih.gov/27797930/
Sehgal NKR, Tronieri JS, Rader B, Ungar L, Guntuku SC. "Self-Reported Side Effects Among Reddit Users Taking Unapproved Retatrutide." medRxiv, posted 3 June 2026, DOI 10.64898/2026.05.28.26352819. Preprint, not peer reviewed. Source of the 7,823-user symptom percentages, of the statement that appetite-suppression terms were excluded before the denominator was computed, and of the limitations quoted in this article.
Sehgal NKR, Tronieri JS, Ungar L, Guntuku SC. "Self-reported side effects of semaglutide and tirzepatide in online communities." Nature Health, published 10 April 2026, DOI 10.1038/s44360-026-00108-y. Peer reviewed and published, having first appeared as a medRxiv preprint in March 2026. Source of the 29,172-user figures. A co-author on both papers, JST, reports an investigator-initiated grant on behalf of the University of Pennsylvania from Novo Nordisk and consulting fees from another pharmaceutical company.
US Centers for Medicare and Medicaid Services, National Provider Identifier registry (npiregistry.cms.hhs.gov), queried July 2026. Source of the two named creators' licensed professions and states. We link no clinic or sales page for either.
Medscape Medical News, reporting on the use of unapproved retatrutide, source of the quoted remark by Courtney Younglove, MD, founder and medical director of Heartland Weight Loss.
Grosicki GJ, Kim J, Fielding F, et al. "Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference." American Journal of Physiology Heart and Circulatory Physiology 2025;328(2):H235-H241. PMID 39705534. Six of the seven authors are affiliated with WHOOP Inc., the manufacturer of the wearable used. https://pubmed.ncbi.nlm.nih.gov/39705534/
Pop-Busui R, Rosin SP, Butera NM, et al. "Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The GRADE Cohort." Diabetes Care 2025;48(11):1960-1970. PMID 40986645. https://pubmed.ncbi.nlm.nih.gov/40986645/
Greco C, Santi D, Brigante G, et al. "Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis." Diabetes and Metabolism Journal 2022;46(6):901-911. PMID 35410110. https://pubmed.ncbi.nlm.nih.gov/35410110/
Ganeshalingam AA, Uhrenholt NG, Arnfred S, et al. "Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30 weeks' treatment with semaglutide." Cardiovascular Diabetology Endocrinology Reports 2026;12(1):2. PMID 41555458. https://pubmed.ncbi.nlm.nih.gov/41555458/
Smits MM, Tonneijck L, Muskiet MHA, et al. "Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial." European Journal of Endocrinology 2017;176(1):77-86. PMID 27777261. https://pubmed.ncbi.nlm.nih.gov/27777261/
Rubino DM, Greenway FL, Khalid U, et al. "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial." JAMA 2022;327(2):138-150. PMID 35015037. https://pubmed.ncbi.nlm.nih.gov/35015037/
Marso SP, Bain SC, Consoli A, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes" (SUSTAIN-6). New England Journal of Medicine 2016;375:1834-1844. PMID 27633186. https://pubmed.ncbi.nlm.nih.gov/27633186/
Nicholls SJ, Pavo I, Bhatt DL, et al. "Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes" (SURPASS-CVOT). New England Journal of Medicine 2025;393:2409-2420. PMID 41406444. https://pubmed.ncbi.nlm.nih.gov/41406444/
Weng CH, Cherukuru R, Chou CC, et al. "Glucagon-like peptide-1 receptor agonists and new-onset atrial fibrillation in adults with diabetes or obesity: a multinational cohort study." Diabetes Research and Clinical Practice 2026;239:113454. PMID 42480717. https://pubmed.ncbi.nlm.nih.gov/42480717/
Eli Lilly and Company. TRIUMPH-3 topline results, press release, 23 July 2026. The four major-adverse-cardiovascular-event hazard ratios quoted here are from that release.
ClinicalTrials.gov: NCT06662383, "A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity", phase 3, 800 participants, primary completion November 2026; and NCT06383390 (TRIUMPH-Outcomes), phase 3, 10,000 participants, primary completion February 2029. Both recorded as active and no longer recruiting.
Energy-deficit literature: Keys A, Brozek J, Henschel A, Mickelsen O, Taylor HL. "The Biology of Human Starvation." University of Minnesota Press, 1950 (the Minnesota semi-starvation experiment, 36 participants), together with randomised crossover work on low energy availability in active adults comparing 15 against 45 kcal per kilogram of fat-free mass per day.

Research disclaimer: All content serves scientific information only. Retatrutide is not approved as a medicine in any jurisdiction and is supplied by us for laboratory research use only, not for human consumption. Trial figures are reported as published study results and are not statements about what any individual would experience.

Why this question is harder than it looks

What the trial actually recorded

The half of the trial that rarely gets quoted

Is retatrutide worse for heart rate than tirzepatide?

Does the rise translate into harm?

Heart-rate variability: the part with no data at all

Why a wearable can show all of this without the compound being the cause

The fatigue question, and the trial number nobody quotes

The two community claims, examined

What the creators and the communities say

The part of the community evidence that has numbers

What would actually settle these questions

The compounds discussed here

FAQ

How much does retatrutide raise heart rate?

Does the heart-rate increase go away?

Is a 6 bpm increase clinically significant?

Does retatrutide raise heart rate more than tirzepatide?

What happened to blood pressure in the same trial?

Is there any data on retatrutide and heart-rate variability?

What did that liraglutide HRV trial find?

Can a wearable HRV drop be attributed to the compound?

Is fatigue a documented side effect of retatrutide?

How do the online fatigue percentages compare with the trial?

How many people online actually report a heart-rate problem?

Are the videos warning about retatrutide and heart rate reliable?

What are the fatigue rates for the approved compounds?

Does eating too little make the cardiac effects worse?

Is there a recommended rate of weight loss or protein intake for this situation?

Is there evidence for switching from retatrutide to tirzepatide for maintenance?

Does the heart-rate effect reverse after stopping?

What about palpitations or atrial fibrillation?

Who was excluded from the retatrutide trial?

Is retatrutide approved, and how do you supply it?

Sources

Research context for English-speaking buyers